Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients registered with the state’s Department of Public Health can purchase cannabis oil from Georgia’s independent pharmacies.

Oil 98

Oil Patients Access THC 98

Kind Meds (Cannabis Education Blog)

JUNE 27, 2021

At the same time, the pharmaceutical industry has become one of the most powerful businesses in the country. Big Pharma, which includes ten of the largest powers of the pharmaceutical industry, like businesses such as Johnson & Johnson, are heavily influential when it comes to political decisions in the U.S. Nerve pain.

Pharmaceutical 99

Pharmaceutical Chronic Pain Medicine Nerve Pain 99

Cannabis Law Report

AUGUST 12, 2022

. – August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL. ”

Extraction 52

Extraction Pharmaceutical Patients THC 52

CannaMD

NOVEMBER 8, 2021

In recognition of this information, a significant but still limited number of Parkinson’s patients have turned to cannabis as a complementary therapy to traditional pharmaceutical options. A survey of current […].

Patients 103

Patients Therapy Pharmaceutical Marijuana 103

Cannabis Law Report

MAY 26, 2023

Multinational operator to supply pharmaceutical-grade CBD extract for European patients TOCANCIPÁ, Colombia, May 25, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc.

Pharmaceutical 52

Pharmaceutical Extraction Medicine CBD 52

Cannabis Law Report

AUGUST 10, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About MyMD Pharmaceuticals, Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

MMJ Recs

AUGUST 1, 2024

While antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal diagnosis to a manageable chronic condition, patients often endure chronic pain, nausea, appetite loss, and psychological distress. Medical marijuana for HIV/AIDS offers a promising complementary treatment for patients.

Patients 52

Patients Chronic Pain Marijuana Sleep 52

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

NORML

FEBRUARY 14, 2019

SB1719 allows “registered agents” for those patients physically unable to pick up or receive delivery of their medical cannabis, like those in hospice, assisted living facilities, and those who rely on home healthcare providers. Virginia NORML members meet with Senator Dave Marsden. “I am proud to be part of this effort.”

Access 198

Access Patients Legislation Medicine 198

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Project CBD

OCTOBER 26, 2023

I advise my patients to stop using cannabis for 36 to 48 hours prior to chemotherapy and to start again 36 to 48 hours after their session. Phase 2 is the first study level conducted on patients with the disease for which the drug is intended and determines whether it is safe and effective.

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Veriheal

APRIL 7, 2022

The study’s researchers, who voiced concern about the current pharmaceutical treatment for MS, looked at the neurological benefits, clinical challenges, and neuropathologic promise of medical cannabis for MS. In a survey of 5,481 MS patients, 47% considered using MMJ, but only 20% spoke with their physician about it.

Patients 98

Patients Treatment Cannabinoids Pharmaceutical 98

Veriheal

JANUARY 10, 2022

Enter cannabis, the plant medicine that is quickly becoming the remedy of choice for patients who have been diagnosed with breast cancer according to a recently conducted survey that was published in the journal Cancer. Breast Cancer Patients and Medical Cannabis. More cancer patients in the U.S. Over 600 Study Participants .

Patients 98

Patients Treatment Medicine Consumption 98

Cannabis Law Report

NOVEMBER 23, 2020

22 Nov – Blurb… Since 2019, Medicinal Cannabis Clinics has facilitated over 4,000 medical consultations with pre-screened eligible patients and has shown continued month-on-month growth.… The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report.

Pharmaceutical 59

Pharmaceutical Medicine Patients Cannabis 59

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

AUGUST 22, 2021

“The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Veriheal

SEPTEMBER 7, 2022

’s medical cannabis program come on the heels of a previously enacted emergency amendment focused on senior citizens: The Medical Marijuana Patient Access Extension Emergency Amendment Act of 2022 allowed D.C. A Temporary Triumph for Medical Cannabis Patients. The State of Patients’ Rights and Access in America Today.

Patients 98

Patients Programs Access Treatment 98

Medical Marijuana Program Connection

FEBRUARY 2, 2023

The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals JAZZ Epidiolex, a CBD-based medicine, to patients suffering from tuberous. Read More

Patients 52

Patients CBD Pharmaceutical Medicine 52

Cannabis Law Report

JULY 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., About MyMD Pharmaceuticals, Inc. Company plans to initiate Phase II trial with a leading academic institution.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC. Is MMJ Legal In Virginia?

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

AUGUST 27, 2021

The Edmonton, Alberta-based cannabis giant also said that its subsidiary and Ethypharm were selected by the National Agency for the Safety of Medicines and Health Products to supply the entire medical cannabis dried flower range sourced from the company’s EU GMP facility in Denmark Aurora Nordic to French patients as part of the program.

Patients 105

Patients Programs Pharmaceutical Compliance 105

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. This law allows a limited number of patients to use CBD-based medicine with no more than 0.5 percent THC content. View original article.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Despite the recently announced national lockdown in the Netherlands, our CRO is continuing to screen and enroll patients,” stated Daniel Schneeberger, M.D., About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Rex Merchant.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. In addition to his consulting and directorial responsibilities, he maintains an active research program directed towards improving outcomes for stroke patients. Moreau CEO of Algernon Pharmaceuticals Inc. “We About Algernon Pharmaceuticals Inc. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

FEBRUARY 11, 2021

Cannabis has been identified as a potentially effective strategy to decrease opiate usage and the survey wanted to determine how the use of medical cannabis affects opioid prescription usage among patients with chronic pain. They conducted an online survey of patients from three medical practice sites.

Chronic Pain 93

Chronic Pain Patients Clinical Trials Treatment 93

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 96

Patients Research and Development Sleep Clinical Trials 96

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73